Amferia
Saba Atefyekta started their work experience in 2013 as a project assistant at Chalmers University of Technology. They then became an exchange visitor at Northeastern University in the same year. In 2014, Saba began working as a Ph.D. student at Chalmers University of Technology. From 2016 to 2018, they worked as an exchange visitor at Stanford University. In 2018, Saba co-founded Amferia and took on the role of Sales Director and Co-founder. They also held the position of Co-Founder at Amferia.
Saba Atefyekta pursued their education in materials chemistry and nanotechnology at Chalmers University of Technology. Saba obtained a Master of Science (M.S.) degree from the university, completing their studies between the years 2011 and 2014.
This person is not in any teams
Amferia
Amferia develops innovative medical devices to provide solutions to the global antibiotic resistance crisis. Amferia’s core focus is preventive healthcare where the goal is to provide highly efficient anti-infective medical devices that can prevent bacterial infections including those caused by antibiotic resistant bacteria. Our dominant focus iswithin the wound care sector, producing preventive care wound patches for the pressing need to avoid antibiotic resistant skin infections. Amferia’s proprietary anti-infective technology is a result of several years of research from Chalmers University of Technology and is patent protected.